Anti-erbB3 antibody
The present invention relates to an antibody or an antibody fragment thereof which recognizes an extracellular domain of erbB3 and inhibit EGF-like ligand-dependent phosphorylation of erbB3, a DNA encoding the antibody or the antibody fragment thereof, a method of producing the antibody or the antibody fragment thereof, a therapeutic drug including the antibody or the antibody fragment thereof, and therapeutic application using the antibody or the antibody fragment thereof.
1. An antibody or an antibody fragment thereof, wherein the antibody comprises an antibody heavy chain variable region (V H ) comprising SEQ ID NO: 81 and an antibody light chain variable region (V L ) comprising SEQ ID NO: 82, and wherein the antibody and antibody fragment thereof specifically bind to extracellular domain 4 of erbB3 consisting of amino acids 488 to 643 of SEQ ID NO: 3.
2. A pharmaceutical composition comprising the antibody or antibody fragment according to claim 1 and a pharmaceutically acceptable carrier.
3. An antibody composition comprising a first antibody or antibody fragment thereof according to claim 1 and a second antibody or antibody fragment thereof, wherein the second antibody and antibody fragment thereof bind to a domain of erbB3 that is not extracellular domain 4 of erbB3 consisting of amino acids 488 to 643 of SEQ ID NO: 3.
4. The antibody composition according to claim 3 wherein the second antibody or antibody fragment thereof binds with domain 1 or 3 in the extracellular domain of erbB3.
5. The antibody composition according to claim 3 wherein the second antibody comprises an antibody heavy chain variable region (V H ) comprising SEQ ID NO: 57 and an antibody light chain variable region (V L ) comprising SEQ ID NO: 58.
6. The antibody composition according to claim 3 wherein the second antibody comprises heavy chain complementary determining regions (CDRs) 1 to 3 comprising SEQ ID NOS: 59-61, respectively, and light chain CDRs 1 to 3 comprising SEQ ID NOS: 62-64, respectively.
7. A pharmaceutical composition comprising the antibody composition of claim 3 and a pharmaceutically acceptable carrier.
8. An antibody or an antibody fragment thereof, wherein the antibody and the antibody fragment comprise heavy chain complementary determining regions (CDRs) 1 to 3 comprising SEQ ID NOS: 83-85, respectively, and light chain CDRs 1 to 3 comprising SEQ ID NOS: 86-88, respectively, and wherein the antibody and antibody fragment thereof specifically bind to extracellular domain 4 of erbB3 consisting of amino acids 488 to 643 of SEQ ID NO: 3.
9. A pharmaceutical composition comprising the antibody or antibody fragment of claim 8 and a pharmaceutically acceptable carrier.
10. An antibody composition comprising a first antibody or antibody fragment thereof according to claim 8 and a second antibody or antibody fragment thereof, wherein the second antibody and antibody fragment thereof bind to a domain of erbB3 that is not extracellular domain 4 of erbB3 consisting of amino acids 488 to 643 of SEQ ID NO: 3.
11. The antibody composition according to claim 10 wherein the second antibody or antibody fragment thereof binds with domain 1 or 3 in the extracellular domain of erbB3.
12. The antibody composition according to claim 10 wherein the second antibody comprises an antibody heavy chain variable region (V H ) comprising SEQ ID NO: 57 and an antibody light chain variable region (V L ) comprising SEQ ID NO: 58.
13. The antibody composition according to claim 10 wherein the second antibody comprises heavy chain complementary determining regions (CDRs) 1 to 3 comprising SEQ ID NOS: 59-61, respectively, and light chain CDRs 1 to 3 comprising SEQ ID NOS: 62-64, respectively.
14. A pharmaceutical composition comprising the antibody composition of claim 10 and a pharmaceutically acceptable carrier.